| Neuroblastoma patient‐derived orthotopic xenografts retain metastatic patterns and geno‐and phenotypes of patient tumours N Braekeveldt, C Wigerup, D Gisselsson, S Mohlin, M Merselius, ... International journal of cancer 136 (5), E252-E261, 2015 | 116 | 2015 |
| Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort I Tadeo, AP Berbegall, V Castel, P García-Miguel, R Callaghan, ... British journal of cancer 115 (4), 480-489, 2016 | 64 | 2016 |
| Biotensegrity of the extracellular matrix: physiology, dynamic mechanical balance, and implications in oncology and mechanotherapy I Tadeo, AP Berbegall, LM Escudero, T Álvaro, R Noguera Frontiers in oncology 4, 39, 2014 | 63 | 2014 |
| Intragenic anaplastic lymphoma kinase (ALK) rearrangements: Translocations as a novel mechanism of ALK activation in neuroblastoma tumors S Fransson, M Hansson, K Ruuth, A Djos, A Berbegall, N Javanmardi, ... Genes, Chromosomes and Cancer 54 (2), 99-109, 2015 | 62 | 2015 |
| Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion E Villamón, AP Berbegall, M Piqueras, I Tadeo, V Castel, A Djos, ... PLoS One 8 (1), e53740, 2013 | 60 | 2013 |
| Patient-derived xenograft models reveal intratumor heterogeneity and temporal stability in neuroblastoma N Braekeveldt, K Von Stedingk, S Fransson, A Martinez-Monleon, ... Cancer research 78 (20), 5958-5969, 2018 | 54 | 2018 |
| Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours N Braekeveldt, C Wigerup, I Tadeo, S Beckman, C Sandén, J Jönsson, ... Cancer letters 375 (2), 384-389, 2016 | 54 | 2016 |
| Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study AP Berbegall, D Bogen, U Pötschger, K Beiske, N Bown, V Combaret, ... British journal of cancer 118 (11), 1502-1512, 2018 | 53 | 2018 |
| Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN … R Defferrari, K Mazzocco, IM Ambros, PF Ambros, C Bedwell, K Beiske, ... British journal of cancer 112 (2), 290-295, 2015 | 48 | 2015 |
| Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltration AP Berbegall, E Villamón, I Tadeo, T Martinsson, A Cañete, V Castel, ... Neoplasia 16 (6), 471-480, 2014 | 38 | 2014 |
| Impact of extracellular matrix stiffness on genomic heterogeneity in MYCN-amplified neuroblastoma cell line A López-Carrasco, S Martín-Vañó, R Burgos-Panadero, E Monferrer, ... Journal of Experimental & Clinical Cancer Research 39, 1-13, 2020 | 37 | 2020 |
| 11q deletion or ALK activity curbs DLG2 expression to maintain an undifferentiated state in neuroblastoma JT Siaw, N Javanmardi, J Van den Eynden, DE Lind, S Fransson, ... Cell reports 32 (12), 2020 | 36 | 2020 |
| Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors AP Berbegall, E Villamon, M Piqueras, I Tadeo, A Djos, PF Ambros, ... Oncogene 35 (11), 1423-1432, 2016 | 35 | 2016 |
| Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma A Decock, M Ongenaert, R Cannoodt, K Verniers, B De Wilde, G Laureys, ... Oncotarget 7 (2), 1960, 2016 | 33 | 2016 |
| A stiff extracellular matrix is associated with malignancy in peripheral neuroblastic tumors I Tadeo, AP Berbegall, S Navarro, V Castel, R Noguera Pediatric Blood & Cancer 64 (9), e26449, 2017 | 32 | 2017 |
| Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients F Zeka, A Decock, A Van Goethem, K Vanderheyden, F Demuynck, ... JCI insight 3 (23), 2018 | 31 | 2018 |
| Vascular patterns provide therapeutic targets in aggressive neuroblastic tumors I Tadeo, G Bueno, AP Berbegall, MM Fernández-Carrobles, V Castel, ... Oncotarget 7 (15), 19935, 2016 | 29 | 2016 |
| 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma AV Ugolkov, GI Bondarenko, O Dubrovskyi, AP Berbegall, S Navarro, ... Anti-cancer drugs 29 (8), 717-724, 2018 | 27 | 2018 |
| Quantitative modeling of clinical, cellular, and extracellular matrix variables suggest prognostic indicators in cancer: a model in neuroblastoma I Tadeo, M Piqueras, D Montaner, E Villamón, AP Berbegall, A Cañete, ... Pediatric research 75 (2), 302-314, 2014 | 20 | 2014 |
| Comparative study of MLPA-FISH to determine DNA copy number alterations in neuroblastic tumors E Villamón, M Piqueras, AP Berbegall, I Tadeo, V Castel, S Navarro, ... Histology and histopathology, Vol. 26, nº 3 (2011), 2011 | 18 | 2011 |
